Plain-English translation of NCT06885853 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a booster dose of MVA-BN vaccine to see how long protection against monkeypox lasts after the initial vaccination series. Researchers want to understand whether the booster strengthens immunity and keeps people protected over time, especially for men already receiving HIV prevention medication who are at higher risk of monkeypox exposure.
Earlier studies showed that antibodies (the body's defense proteins) from the original vaccine doses became undetectable after one year, raising concerns about long-term protection. This trial will gather information about whether a booster dose can restore and maintain that protection, which is crucial for deciding future vaccination recommendations.
You likely qualify if…
You likely don't qualify if…
You would receive a booster injection of the monkeypox vaccine during a clinic visit. Researchers would then monitor your immune response through blood tests and check for any side effects at multiple follow-up visits over time. The study is designed to track how long your body's protection lasts after this booster dose.
AI-generated summary from trial data · Jun 14, 2026 · Not medical advice
France
Enrollment target
~90 participants
Started
May 2025
Primary completion
November 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in May 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liem Binh Luong Nguyen, Degree medical doctor
Assistance Publique - Hôpitaux de Paris
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.